RxDoctor Payments Data

Mark Davis

Psychiatric/Mental Health · Walla Walla, WANPI 1265296412

Payments from drug & device makers

$2,492in general payments, 2019–2025

Across 67 payments — averaging $37.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$551
  • E.r. Squibb & Sons, L.L.C.$379
  • Neurocrine Biosciences, Inc.$306
  • Axsome Therapeutics, Inc.$295
  • Teva Pharmaceuticals USA, Inc.$288
  • Otsuka America Pharmaceutical, Inc.$262
  • plus $412 from 4 others

What the payments were for

  • Food & beverage$2,492100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,492 in reported general payments places this provider in the 85th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$8,911
Medicare patients
33
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate19$62,224
RexultiBrexpiprazole14$20,385
VraylarCariprazine Hcl11$15,638
Aripiprazole57$2,603
Atomoxetine Hcl15$2,011
Haloperidol Decanoate42$1,444
Divalproex Sodium ErDivalproex Sodium22$1,214
Quetiapine Fumarate81$1,060
Olanzapine93$992
Mirtazapine30$829
Venlafaxine Hcl ErVenlafaxine Hcl23$718
Temazepam12$702
Thioridazine Hcl16$689
Carbamazepine17$647
Benztropine Mesylate47$579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$220$62,22419 claims
Otsuka America Pharmaceutical, Inc.Rexulti$262$20,38514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Walla Walla

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →